Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | TACR2 | P21452 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SHBG | P04278 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5304765 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL5303025 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL5296180 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL5815570 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL10645352 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL5299615 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL5299310 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL5299368 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL5305758 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL5294380 | 0.98 | HTR2A (0.61) | HTR2ACYP3A4ESR1ADRA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1800129-A1 | POLYCATIONIC POLYMER COATINGS FOR IMMOBILIZING BIOLOGICAL SAMPLES | Tripath Imaging, Inc. (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006034385-A1 | POLYCATIONIC POLYMER COATINGS FOR IMMOBILIZING BIOLOGICAL SAMPLES | TRIPATH IMAGING, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-9891497-B2 | Electrochromic device and method for producing electrochromic device | RICOH COMPANY, LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| WO-2006131234-A1 | COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | HTR2A 4368/4885CYP3A4 941/4885ESR1 3942/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | HTR2A 2754/4885CYP3A4 592/4885ESR1 1904/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | HTR2A 3648/4885CYP3A4 562/4885ESR1 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.